Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued [Seeking Alpha]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Seeking Alpha
Despite strong results, Sanofi announced today it has replaced CEO Paul Hudson with former employee Belén Garijo, signaling urgency for improved execution and R&D innovation. Sanofi remains heavily reliant on Dupixent, which generated ~€15.7bn, or 36% of total 2024 revenues. The vaccine division faces pressure, with key vaccine sales declining and U.S. market headwinds compounding strategic challenges. Nevertheless, Sanofi's strong pipeline and new launches give me confidence the company can maintain a growth trajectory, which makes stock look somewhat undervalued today. Looking for a portfolio of ideas like this one? Members of Haggerston BioHealth get exclusive access to our subscriber-only portfolios. Learn More » Luis Alvarez/DigitalVision via Getty Images Investment Overview Sanofi ( SNY ), native ticker Euronext Paris: SAN, reported its Q4 and full-year earnings on January 29th, announcing net sales up 9.9% year-on-year, to €43.6bn in 2025, and net income up 12%,
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Prices, pipelines and patent cliffs: Inside pharma's big reset [CNBC]CNBC
- Analysis-Sanofi's new CEO needs to fix drug pipeline and navigate Trump [Yahoo! Finance Canada]Yahoo! Finance Canada
- Sanofi replaces CEO Paul Hudson with outgoing Merck KGaA head [Yahoo! Finance]Yahoo! Finance
- How founders can tap women investors as a competitive advantage in 2026 [Fortune]Fortune
- Does Sanofi's CEO Overhaul And Governance Shift Change The Bull Case For Sanofi (ENXTPA:SAN)? [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 2/12/26 - Form 6-K
- 2/11/26 - Form 13F-HR
- 2/10/26 - Form 6-K
- SNY's page on the SEC website